Associate Professor of Medicine; The University of Chicago. Medical Director, Clinical Outpatient Cancer Center
Oncology
Dr. Chadi Nabhan, MD
|
|
Give Review
Chadi Nabhan works in the field of Oncology. He has 2 awards "Regional Top Doctor" and "Top MD". Chadi Nabhan, MD is a published physician. He published 68 publications, including: 'The alternatively spliced type II corticotropin-releasing factor receptor, stably expressed in LLCPK-1 cells, is not well coupled to the G protein(s).' He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin Lymphoma.
- Ibrutinib-induced pneumonitis in patients with chronic lymphocytic Leukemia.
- Oncology Pathways-Preventing a Good Idea From Going Bad.
- The evolving role of lenalidomide in non-Hodgkin Lymphoma.
- MYC-associated and double-hit Lymphomas: A review of pathobiology, prognosis, and therapeutic approaches.
- Chronic lymphocytic Leukemia: a clinical review.
- Factors predicting survival in peripheral T-cell lymphoma in the USA: a population-based Analysis of 8802 patients in the modern era.
- Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective Analysis.
- The impact of race, ethnicity, age and sex on clinical outcome in chronic lymphocytic Leukemia: a comprehensive Surveillance, Epidemiology, and End Results analysis in...
- A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naïve castration-resistant prostate Cancer.
- Extramedullary chronic lymphocytic Leukemia: Systematic analysis of cases reported between 1975 and 2012.
- Examination of the follicular Lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predomin...
- Lymphangitic pulmonary metastases in castrate-resistant proState adenocarcinoma.
- Diffuse large B-cell Lymphoma: is there a place for autologous hematopoietic stem cell transplant in first remission in the era of chemo-immunotherapy?
- Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States: report from the National LymphoCare Study.
- A retrospective multicenter Analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era.
- Analysis of very elderly (≥80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome.
- Classifying Cytogenetics in Patients with AML in Complete Remission Undergoing Allogeneic Transplantation: A CIBMTR Study.
- Bortezomib (velcade), rituximab, cyclophosphamide, and dexamethasone combination regimen is active as front-line therapy of low-grade non-hodgkin Lymphoma.
- The emerging role of ofatumumab in the treatment of chronic lymphocytic Leukemia.
- Liver involvement with Acute myeloid leukemia.
- Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients.
- Biologic agent activity in chronic lymphocytic Leukemia: a framework for future therapies.
- Novel approaches and future directions in castration-resistant prostate Cancer.
- Disclosing the Cancer diagnosis:the myth and the truth.
- Sipuleucel-T immunotherapy for castration-resistant prostate Cancer.
- I need a hug ... please.
- Hematopoietic SCT for mantle cell Lymphoma: is it the standard of care?
- Aplastic anemia surfacing after treatment of Acute promyelocytic leukemia: The Dameshek riddle.
- Docetaxel and oxaliplatin as first-line therapy for advanced non-small cell lung Cancer: a phase II trial.
- Erlotinib has moderate single-agent activity in chemotherapy-naïve castration-resistant prostate Cancer: final results of a phase II trial.
- Clofarabine in relapsed Lymphoma: what is the optimal dose?
- ''How could you do this, doctor . . .?''.
- Extragonadal choriocarcinoma in ulcerative colitis.
- Frontline therapy for chronic lymphocytic Leukemia: the dilemma continues.
- Is chemotherapy the standard for asymptomatic androgen-independent prostate Cancer?
- Controversies in the front-line management of chronic lymphocytic Leukemia.
- Mitomycin-C/5-fluorouracil/leucovorin and hyperfractionated radiation therapy for Rectal carcinoma: a phase II study with long-term follow-up.
- Hodgkin's Lymphoma involving the CNS.
- It is follicular... . so, why CHOP?
- Minimal residual disease in Chronic lymphocytic leukaemia: is it ready for primetime?
- Thalidomide and dexamethasone for newly diagnosed multiple Myeloma: is this really the standard of care?
- A simple wish...Unfulfilled.
- Chronic lymphocytic Leukemia: to transplant or not to transplant... that is the question?
- Erlotinib in lung Cancer.
- The emerging role of alemtuzumab in chronic lymphocytic Leukemia.
- Should we transplant indolent Lymphoma?
- Chemotherapy for advanced prostate Cancer.
- 8-amino-adenosine is a potential therapeutic agent for multiple Myeloma.
- Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in Acute myeloid leukemia patients age 65 or older.
- A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic Leukemia (CLL).
- Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive Syndrome/veno-occlusive disease.
- Phase II trial of arsenic trioxide in relapsed and refractory Acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old.
- In vitro assessment of nucleoside Analogs in multiple myeloma.
- Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic Leukemia: dawn of a new era.
- Current status of monoclonal antibody therapy for chronic lymphocytic Leukemia.
- Current concepts in the diagnosis and management of thrombotic Thrombocytopenic purpura.
- Hereditary and acquired defects in the fibrinolytic System associated with thrombosis.
- Secondary Acute myelogenous leukemia with MLL gene rearrangement following radioimmunotherapy (RAIT) for non-Hodgkin''s lymphoma.
- Caspase activation is required for gemcitabine activity in multiple Myeloma cell lines.
- Management of Acute promyelocytic leukemia.
- Early phase I/II trials with gemtuzumab ozogamicin (Mylotarg) in Acute myeloid leukemia.
- Conceptual aspects of combining rituximab and Campath-1H in the treatment of chronic lymphocytic Leukemia.
- Acute promyelocytic leukemia: evolving therapeutic strategies.
- Gemcitabine in hematologic malignancies.
- The role of bone marrow transplantation in Acute promyelocytic leukemia.
- The alternatively spliced type II corticotropin-releasing factor receptor, stably expressed in LLCPK-1 cells, is not well coupled to the G protein(s).
Schools
University Of Damascus
Loyola University
Nw University
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
- Top MD
Education
-
McGaw Medical Center of Northwestern University -
Loyola University -
Damascus University Faculty of Medicine
Hospital
-
Advocate Lutheran General Hospital -
University of Chicago Medical Center
Drug Facts
| NPI NUMBER | 1972563682 | |
| NPPES Provider LastName | NABHAN | |
| NPPES Provider FirstName | CHADI | |
| NPPES Provider ZIPCode | 600681270 | |
| NPPES Provider State | IL | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 250.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 16.0 | |
| Percent Opioid Claims | 6.4 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1972563682 |
| Last Name Of The Provider | NABHAN |
| First Name Of The Provider | CHADI |
| View All |
Similar Doctors
|
Dr. Irfan A. Mirza, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mary F. Mulcahy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Philip Bonomi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elizabeth M. Hyjek, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Javed Imam, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Silviya V. Velinova, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Boris Pasche, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John L. Kennedy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lydia Usha, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nagarpu S. Reddy, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Kochurani J. Maliekel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vassiliki Saloura, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Randy F. Sweis, MD
This Doctor is OpenDoctor Recommended.
|